Antibodies against the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, have shown a survival benefit in mCRC patients with KRAS wild-type tumours both as monotherapy [1,2] and when added to chemotherapy[3,4]. Here, KRAS is linked to neoplasm.